Ra­di­oli­gands are go­ing on air: Ak­tis gains third Big Phar­ma backer

In­trigue in ra­di­oli­gands, or drugs made of ra­dioac­tive atoms at­tached to hom­ing pro­teins, has been grow­ing in the past few years, par­tic­u­lar­ly for treat­ing metasta­t­ic prostate can­cer. No­var­tis and En­do­cyte have led that charge with Plu­vic­to, which is aimed at PS­MA, an anti­gen over­ex­pressed in prostate can­cer cells.

Oth­er biotechs have al­so emerged, in­clud­ing one lit­er­al­ly named PS­MA Ther­a­peu­tics, hop­ing to go af­ter that same tar­get with a tar­get­ed ra­di­a­tion drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER